STRIPPOLI, SABINO
 Distribuzione geografica
Continente #
NA - Nord America 556
EU - Europa 159
AS - Asia 106
SA - Sud America 5
AF - Africa 1
OC - Oceania 1
Totale 828
Nazione #
US - Stati Uniti d'America 552
SG - Singapore 60
SE - Svezia 35
CN - Cina 34
IT - Italia 31
DE - Germania 30
GB - Regno Unito 18
FI - Finlandia 8
RU - Federazione Russa 8
FR - Francia 7
IE - Irlanda 7
VN - Vietnam 5
BR - Brasile 4
CA - Canada 4
IN - India 4
NL - Olanda 4
BE - Belgio 3
UA - Ucraina 2
AR - Argentina 1
AT - Austria 1
AU - Australia 1
JP - Giappone 1
LT - Lituania 1
NO - Norvegia 1
PK - Pakistan 1
PT - Portogallo 1
RO - Romania 1
SK - Slovacchia (Repubblica Slovacca) 1
TH - Thailandia 1
ZA - Sudafrica 1
Totale 828
Città #
Fairfield 94
Chandler 61
Woodbridge 55
Ashburn 49
Seattle 39
Singapore 37
Cambridge 34
Nyköping 33
Houston 29
Ann Arbor 21
Wilmington 20
New York 14
Beijing 13
Bari 11
Lawrence 11
Inglewood 10
Roxbury 10
Des Moines 7
Dublin 7
San Diego 7
Dearborn 6
Nanjing 6
Dong Ket 5
Helsinki 5
Jacksonville 5
Los Angeles 4
Munich 4
Princeton 4
Amsterdam 3
Bologna 3
Brussels 3
Mottola 3
Ottawa 3
Paris 3
Pune 3
Kunming 2
London 2
Shanghai 2
Terlizzi 2
Wuhan 2
Boardman 1
Bratislava 1
Brooklyn 1
Cerignola 1
Chiswick 1
Cluj-napoca 1
Conceição do Jacuípe 1
Edinburgh 1
Frankfurt am Main 1
Groningen 1
Guangzhou 1
Hebei 1
Hounslow 1
Jiaxing 1
Krasnodar 1
Lisbon 1
Lobería 1
Marseille 1
Milan 1
Monmouth Junction 1
New Bedfont 1
Noicattaro 1
Oslo 1
Ourinhos 1
Prescot 1
Prineville 1
Redwood City 1
Santa Clara 1
Shenyang 1
Shenzhen 1
Sorocaba 1
Southwark 1
Sydney 1
Taranto 1
Teresópolis 1
Tokyo 1
Toronto 1
Triggiano 1
Vienna 1
Washington 1
Totale 672
Nome #
Ocular toxicity in metastatic melanoma patients treated with mitogen-activated protein kinase kinase inhibitors: A case series 143
Influence of melanocortin-1 receptor (MC1R) polymorphisms on clinical outcomes of patients with metastatic melanoma harboring the BRAF mutation and treated with BRAF inhibitors 119
Detrimental effects of melanocortin-1 receptor (MC1R) variants on the clinical outcomes of BRAF V600 metastatic melanoma patients treated with BRAF inhibitors 112
The Management of Oligoprogression in the Landscape of New Therapies for Metastatic Melanoma 104
The search for a melanoma-tailored chemotherapy in the new era of personalized therapy: a phase II study of chemo-modulating temozolomide followed by fotemustine and a cooperative study of GOIM (Gruppo Oncologico Italia Meridionale) 85
Negative influence of Melanocortin-1 receptor (MC1R) polymorphisms on clinical outcomes of metastatic melanoma (MM) patients (pts) harboring BRAF mutation and treated with BRAF inhibitors (BRAFi) 71
Anti-PD1 antibodies in patients aged ≥ 75 years with metastatic melanoma: A retrospective multicentre study 52
An Italian Retrospective Survey on Bone Metastasis in Melanoma: Impact of Immunotherapy and Radiotherapy on Survival 49
Case Report: Lymphocytosis Associated With Fatal Hepatitis in a Thymoma Patient Treated With Anti-PD1: New Insight Into the Immune-Related Storm 46
The β-adrenergic receptor antagonist propranolol offsets resistance mechanisms to chemotherapeutics in diverse sarcoma subtypes: a pilot study 41
null 29
Oversecretion of Cytokines and Chemokines in Lupus Nephritis Is Regulated by Intraparenchymal Dendritic Cells A Review 18
BRAFV600E;K601Q metastatic melanoma patient-derived organoids and docking analysis to predict the response to targeted therapy 17
Melanoma Brain Metastases: A Retrospective Analysis of Prognostic Factors and Efficacy of Multimodal Therapies 13
Circulating extracellular vesicles are monitoring biomarkers of anti-PD1 response and enhancer of tumor progression and immunosuppression in metastatic melanoma 8
Totale 907
Categoria #
all - tutte 4.747
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 4.747


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020132 0 0 0 0 18 17 13 20 25 15 17 7
2020/2021192 12 13 10 12 28 36 18 10 7 22 15 9
2021/202288 4 0 1 1 4 10 1 1 14 7 18 27
2022/2023154 21 32 7 14 16 17 4 18 21 2 2 0
2023/202491 4 16 5 2 11 29 0 5 2 3 0 14
2024/2025106 18 7 23 27 31 0 0 0 0 0 0 0
Totale 907